We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Tissue Regenix Group

New strategy delivering results

Update | 04 February 2019

Scancell

Interim results show progress being maintained

Update | 31 January 2019

Mereo BioPharma

Executing a well articulated strategy

Outlook | 31 January 2019

Scancell

Missing out on the CRUK Grand Challenge

Lighthouse | 23 January 2019

MaxCyte

Picking up the pace

Update | 15 January 2019

Nexstim

Achieving commendable outcomes in depression

Update | 20 December 2018

e-therapeutics

First commercial deal secured with global diabetes leader

Update | 10 December 2018

Mereo BioPharma

Merger with NASDAQ-listed OncoMed

Lighthouse | 07 December 2018

e-therapeutics

New insights from Parkinson’s disease collaboration

Update | 06 December 2018

MaxCyte

Momentum building in Cell Therapy and CARMA

Outlook | 05 December 2018
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
142 results found.